I was 20 years old when I started the company that would nearly kill me. I was at university. Facebook had just sprung onto everyone's conscious. I started a social media brand called Unilad. I remember running down to my housemates's room and saying, "Philip, what do you think of the name Unilad. " and he blew out this puff of marijuana smoke and said, "Yeah, that's really cool, man. " So, with a focus group of Phillip, the name was chosen. But I had a problem. How do I get people to care about Unilad? And ...

Hello everybody. My name is Esther Hail and as Kayla said, I'm going to be telling you about the brain. I have two goals for this talk today.The first is to explain a little bit about how the brain works and the second is to make a simple model of it. A very simple model. A very very simple model.This is your brain. Not your brain specifically, the human brain. The brain was originally thought to be an organ just used for temperature regulation, mainly of the blood.Then once psych psychiatrists and physicia ...

Summary of Conference Call Company and Industry Overview - The discussion centers around **Alkermes**, a biopharmaceutical company focused on developing treatments for central nervous system disorders, particularly narcolepsy and other sleep-related conditions. The company is optimistic about its **orexin program** and its potential impact on the market in 2026 [2][3]. Core Insights and Arguments - **Positive Outlook**: Alkermes is experiencing a positive sentiment regarding its orexin program, especially with the anticipated approval of Takeda's drug, which is expected to set market pricing and demonstrate launch trajectories [2][3]. - **Differentiation Factors**: The key differentiators for Alkermes' drug compared to competitors will be **dosing flexibility** and the ability to treat various types of hypersomnolence without needing differential diagnoses [4][6]. - **Clinical Trial Insights**: In clinical trials, over 70% of patients reported normalcy on the **Epworth Sleepiness Scale (ESS)** at the highest dose, indicating strong efficacy. The company emphasizes the importance of various endpoints beyond the **Maintenance of Wakefulness Test (MWT)** [13][15]. - **Dosing Strategy**: Alkermes plans to offer a range of dosing options, including once-daily and split doses, to cater to patient needs and lifestyle preferences [5][6]. Additional Important Points - **Market Pricing Strategy**: The company is considering pricing strategies in a post-Inflation Reduction Act (IRA) environment, where orphan medications are priced between **$300,000-$400,000**. Alkermes aims to avoid setting a lower price outside the U.S. that could influence domestic pricing [46][47]. - **Expansion into Other Indications**: Alkermes is exploring additional indications for its orexin agonists, including **ADHD** and **fatigue** in conditions like **multiple sclerosis (MS)** and **Parkinson's disease**. The company believes there is a significant unmet clinical need in these areas [49][51]. - **Regulatory Pathways**: For fatigue, Alkermes is working with the FDA to establish a regulatory pathway, utilizing validated endpoints to capture clinical experiences [54][56]. - **LUMRYZ Acquisition**: The acquisition of LUMRYZ is seen as valuable, particularly for its indication in idiopathic hypersomnia (IH), which is expected to contribute to growth in the market [57][58]. - **Market Dynamics**: The narcolepsy market has approximately **200,000** patients in the U.S., with only **80,000** currently treated. The company anticipates that new effective oral medications will increase diagnosis rates and treatment uptake [61][62]. This summary encapsulates the key points discussed during the conference call, highlighting Alkermes' strategic positioning, product differentiation, and market opportunities.

At the moment, ADHD is considered something you either have or you don’t. This binary approach to diagnosis has two consequences https://t.co/7M6HChQs0q ...

Summary of Alkermes Conference Call Company Overview - **Company**: Alkermes - **Event**: 2026 TD Cowen Healthcare Conference - **Key Speaker**: Richard Pops, Chairman and CEO Industry Focus - **Primary Industry**: Sleep Medicine - **Key Products**: Alixorexton, LUMRYZ, Avadel acquisition Core Points and Arguments 1. **Business Transition**: Alkermes has undergone significant changes in 2025, solidifying its position in the sleep medicine market, particularly with the orexin franchise and the acquisition of Avadel [2][3] 2. **Market Position**: The company is now a major player in the sleep medicine market, preparing for the launch of alixorexton, supported by a strong and cash-generative base business [3] 3. **Acquisition Rationale**: The acquisition of Avadel was strategic, enhancing the company's presence in sleep centers and preparing for the alixorexton launch, which is expected to shift the launch curve positively [4][7] 4. **Unmet Needs in Narcolepsy**: There is a significant gap between the prevalence of narcolepsy (approximately 200,000 patients in the U.S.) and those treated (about 80,000), indicating a large market opportunity [15] 5. **Orexin Compounds**: The company is investigating the ideal dosing for orexin agonists, with promising data from Phase 2 studies indicating safety and efficacy [17][18] 6. **Phase 3 Program**: Alkermes is initiating a Phase 3 program with three studies focused on NT-1 and NT-2, with primary endpoints including the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) [24][25] 7. **Cognitive and Fatigue Outcomes**: The company has observed significant improvements in cognitive complaints and fatigue in patients, which are critical for treatment success [56][57] Additional Important Content 1. **Base Business Strength**: Alkermes has transformed from a royalty-based business to a proprietary products business, with expectations of $1.4 billion from proprietary products in 2026 [59][60] 2. **Commercial Strategy**: The acquisition of Avadel is expected to broaden the commercial portfolio and increase profitability, allowing for aggressive investment in the pipeline [60][61] 3. **Future Opportunities**: Alkermes is exploring additional indications for orexin drugs, including ADHD and fatigue, with initial proof of concept data expected soon [46][48] 4. **Side Effect Profile**: The orexin compounds have a mild to moderate side effect profile, with insomnia being the most common, which tends to diminish over time [39][40] 5. **Business Development**: The company is open to tuck-in business development deals that leverage its clinical and scientific capabilities but is currently focused on executing its late-stage and earlier-stage programs [63][64] This summary encapsulates the key points discussed during the conference call, highlighting Alkermes' strategic direction, market opportunities, and product development plans.

At the moment, ADHD is considered something you either have or you don’t. This binary approach to diagnosis has two consequences https://t.co/HIp1ODyrkg ...

A new study shows that menopause makes ADHD symptoms worse. https://t.co/YKLIj45GOF ...

主创：何嘉琦 魏冯 转自：四川在线 1月30日，成龙在发视频分享自己的生活，他聊到自己被ADHD困扰的情况，引发关注。什么是ADHD？如何诊断和科学干预？本期"健康科代 表"特别邀请到四川省人民医院温江院区/四川省精神医学中心综合心身/儿少科主任黄雨兰，为我们答疑。 ...

I discovered I have ADHD while on vacation, writes WSJ's Katherine Bindley. Then I went down a rabbit hole—of information and disinformation—as I figured out what to do next. https://t.co/dZaykXfrpx https://t.co/9prdlHQBnf ...

Poznajcie Adama. Ja i on znamy się od dawna, bo od trzeciego tygodnia życia. A poznaliśmy się jako cewka nerwowa i od tamtej pory jesteśmy nierozłączni.Pierwsze kroki razem. Oczywiście pierwszy wypadek na rowerze, no jakżeby inaczej. Oczywiście razem i te wszystkie spontaniczne zmiany planów, tak.To też z Adamem, my razem. Adam to jest mój mózg. On jest błyskotliwy, kreatywny, no i taki gadatliwy.Ale Adam ma też swoją gorszą stronę, taką ciemną stronę, bo Adam, słuchajcie, jest bardzo wymagający, bardzo cał ...